A blood test replaces the lumbar puncture The FDA approved on August 20, 2026, the clinical use of PrecivityAD2, a blood test developed by C2N Diagnostics along

Un análisis de sangre reemplaza a la punción lumbar La FDA aprobó el 20 de agosto de 2026 el uso clínico de PrecivityAD2, un análisis de sangre desarrollado por

FDA Clearance Builds on C2N’s Legacy of Delivering Transformative Solutions to Address Alzheimer’s Disease Crisis    PrecivityAD2® Becomes the First FDA-Cleared Test Powered by ...

In a move that could help drastically slow the advancement of Alzheimer's disease (AD), the US Food and Drug Administration (FDA) has cleared C2N Diagnostics' PrecivityAD2 blood test for patients as y...

This is the third blood-based biomarker test for Alzheimer’s disease to be cleared by the FDA, and the first cleared for use in patients as young as 40.

Welcome back to Instagram. Sign in to check out what your friends, family & interests have been capturing & sharing around the world.

PrecivityAD2 is the first blood-based biomarker for people as young as 40 with cognitive symptoms

The FDA has cleared the first Alzheimer's blood test for symptomatic patients as young as 40. The test measures amyloid and tau biomarkers from a single blood draw and identified positive biomarkers with 97.6% accuracy in a validation study. New Atlas reports: PrecivityAD2 is a single blood test th...

The U.S. Food and Drug Administration (FDA) has cleared for marketing an innovative blood test with underlying technology invented at Washington University School of Medicine in St. Louis for the early diagnosis of Alzheimer's disease. The test, known as PrecivityAD2, was developed and validated by C2N Diagnostics, a WashU startup company. PrecivityAD2 is a blood-based diagnostic test cleared by the FDA to aid in identifying the presence of amyloid plaques in the brain associated with Alzheimer's disease in certain patients. Unlike some other FDA-cleared blood-based tests that use immunoassay methods to analyze biomarkers associated with Alzheimer's, PrecivityAD2 uses high-resolution mass spectrometry to provide quantitative measurements of the biomarkers. The availability of blood-based biomarker testing may help clinicians evaluate patients for Alzheimer's disease using a less invasive approach than cerebrospinal fluid testing. Biomarker information may also help inform appropriate clinical management when interpreted together with a patient's clinical history and other diagnostic information. Early detection of Alzheimer's disease is important since the first treatments capable of slowing the progression of the neurodegenerative disease recently became available to patients, and these drugs are more effective when started sooner rather than later. Other promising investigational drugs are in the pipeline. Fundamental technology underlying...

In a move that could help drastically slow the advancement of Alzheimer's disease (AD), the US Food and Drug Administration (FDA) has cleared C2N Diagnostics' PrecivityAD2 blood test for patients as young...

In a move that could help drastically slow the advancement of Alzheimer's disease (AD), the US Food and Drug Administration (FDA) has cleared C2N Diagnostics' PrecivityAD2 blood test for patients as young as 40 who have shown some potential cognitive symptoms of the condition.

The US Food and Drug Administration has granted clearance to C2N Diagnostics' PrecivityAD2 blood test, marking the first such authorization for symptomatic adults aged 40 and older. The test detects amyloid plaques to aid clinical diagnosis but is not a standalone screening tool.

The U.S. Food and Drug Administration has cleared the PrecivityAD2 test for adults 40 and older presenting with signs or symptoms of cognitive impairment and undergoing evaluation for Alzheimer's disease or other forms of cognitive decline.